Garching / Munich, June 15, 2023 – ITM Isotope Applied sciences Munich SE (ITM), a number one radiopharmaceutical biotech firm, as we speak introduced that it’ll host a multidisciplinary symposium titled, “Investing within the Way forward for Theranostics: Aligning Provide to Scientific Want,” on the Society of Nuclear Medication and Molecular Imaging (SNMMI) Therapeutics Convention, held from June 24-27 in Chicago, Illinois, USA. The symposium will happen on June 25, from 6:30 pm to 7:30 pm CST in McCormick Place, Lakeside Middle, Room E450b.
Moderated by Roger Estafanos, U.S. Normal Supervisor at ITM, the panel will characteristic three knowledgeable audio system spanning completely different disciplines inside the discipline: Harshad Kulkarni, MD, Chief Medical Advisor at Daring Superior Medical Future (BAMF) Well being; Neil Quigley, M.Sc., International Product Supervisor at ITM; and Ram Mullur, M.Sc., MB, Vice President of Canadian Nuclear Laboratories.
“Notably because the demand for radiopharmaceuticals continues to develop, we worth the chance to convey collectively and share this panel’s experience and distinctive insights into the medical, scientific, and manufacturing features of theranostics,” commented Steffen Schuster, CEO of ITM. “We stay up for facilitating vital discussions by way of our occasion on the SNMMI, a convention that brings collectively main nuclear drugs specialists beneath the shared objective of bettering care and outcomes for sufferers worldwide.”
Symposium & Speaker Particulars:
The symposium will study the present panorama and promising way forward for theranostics from three distinct however equally vital vantage factors: that of the clinician, the radiochemist, and the producer. Understanding the interdependencies of those stakeholders will assist guarantee the worth of this essential modality for sufferers now and nicely into the long run.
Chair: Mr. Roger Estafanos, U.S. Normal Supervisor of ITM, Princeton, New Jersey
Mr. Estafanos is skilled in each the radiopharmaceutical and pharmaceutical industries and was one of many first leaders of the US division of Superior Accelerator Functions (AAA), a Novartis firm.
The Scientific Perspective: Present and Future Utilization of Theranostics
Dr. Harshad Kulkarni evaluations BAMF’s superior expertise and precision drugs platform, the significance of lutetium and gallium in present apply, his expertise with the actinium-225 and insights to the way forward for the theranostic panorama.
Dr. Kulkarni is Chief Medical Advisor of BAMF Well being’s flagship facility in Grand Rapids and beforehand served as attending doctor in control of Radiomolecular Theranostics within the Theranostics Middle for Molecular Radiotherapy and Precision Oncology at Zentralklinik Dangerous Berka, Germany.
The Radiochemical Perspective: Synergy Between Lutetium-177 & Actinium-225
Mr. Neil Quigley discusses the present mass scale availability of lutetium-177, potential guarantees and challenges of actinium-225 manufacturing routes, and addresses the actinium-225 decay chain with an emphasis on dose contribution.
Mr. Quigley, M.Sc. is International Product Supervisor at ITM, Munich and the 2022 recipient of the George-von-Hevesy Prize awarded by the German Society of Nuclear Medication for excellent work within the discipline of radiochemistry.
The Expertise Perspective: Industrial Availability of Actinium-225
Mr. Ram Mullur examines numerous features of actinium-225 starting from its present annual international manufacturing to the rising demand for its analysis and medical use, challenges associated to the scale-up of manufacturing to fulfill business wants, and CNL’s function in its improvement.
Mr. Mullur, M.Sc., MBA is V.P. of Canadian Nuclear Laboratories, an achieved government with greater than 25 years of broad business expertise and at present targeted on additional growing CNL’s actinium-225 program.
About Focused Radionuclide Remedy
Focused Radionuclide Remedy is an rising class of most cancers therapeutics, which seeks to ship radiation on to the tumor whereas minimizing radiation publicity to regular tissue. Focused radiopharmaceuticals are created by linking a therapeutic radioisotope to a concentrating on molecule (e.g., peptide, antibody, small molecule) that may exactly acknowledge tumor cells and bind to tumor-specific traits, like receptors on the tumor cell floor. Because of this, the radioisotope accumulates on the tumor website and decays, releasing a small quantity of ionizing radiation, with the objective of destroying tumor tissue. The exact localization allows focused remedy with doubtlessly minimal impression to wholesome surrounding tissue.
ITM Isotope Applied sciences Munich SE
ITM, a number one radiopharmaceutical biotech firm, is devoted to offering a brand new era of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We goal to fulfill the wants of most cancers sufferers, clinicians and our companions by way of excellence in improvement, manufacturing and international provide. With improved affected person profit because the driving precept for all we do, ITM advances a broad precision oncology pipeline, together with two part III research, combining the corporate’s high-quality radioisotopes with a variety of concentrating on molecules. By leveraging our practically twenty years of pioneering radiopharma experience, central business place and established international community, ITM strives to supply sufferers with simpler focused remedy to enhance medical end result and high quality of life. www.itm-radiopharma.com
ITM Contact
Company Communications
Julia Hofmann / Svenja Gärtner
Telephone: +49 89 329 8986 1500
E-mail: communications@itm-radiopharma.com
Investor Relations
Ben Orzelek
Telephone: +49 89 329 8986 1009
E-mail: Ben.Orzelek@itm-radiopharma.com
Attachment
Adblock take a look at (Why?)